Home About us Contact
|
Home About us Contact | ||
|
|
||
Lipid Lowering Drugs (lipid + lowering_drug)
Selected AbstractsInformation search in heuristic decision makingAPPLIED COGNITIVE PSYCHOLOGY, Issue 4 2010Mandeep K. Dhami Simple heuristics of the type introduced by Gigerenzer, Todd, and The ABC Research Group (1999) embody principles for information search, stop and decision making. These heuristics suggest that such processes are simple. In an analysis of general practitioners' (GPs) information search and decision-making behaviour when prescribing a lipid lowering drug, we examined whether information search was simple, and whether a heuristic that predicts a simple decision-making process was also accurate at describing information search. We found that GPs' information search behaviour was simple in that it demonstrated characteristics of the matching heuristic (e.g. stopping rule). In addition, although the matching heuristic which correctly predicted on average 75% of GPs' decisions used significantly fewer cues on average than the GPs did in the information search task, it was reasonably accurate in describing order of information search. These findings have implications for the validity of simple heuristics describing both information search and decision making. Copyright © 2009 John Wiley & Sons, Ltd. [source] Liver fibrosis attributed to lipid lowering medications: two casesJOURNAL OF INTERNAL MEDICINE, Issue 3 2001Z. Punthakee Abstract. Punthakee Z, Scully LJ, Guindi MM, Ooi TC (Department of Medicine, Division of Gastroenterology, Department of Pathology and the Laboratory of Medicine and the Division of Endocrinology and Metabolism, The Ottawa Hospital , Civic Campus, University of Ottawa, Ottawa, Canada). Liver fibrosis attributed to lipid lowering medications: two cases (Case Report). J Intern Med 2001; 250: 249,254. We identified two cases of chronic active hepatitis with liver fibrosis induced by lipid lowering drugs of the statin and fibrate classes despite regular monitoring of transaminases. There are few reports of clinically significant hepatitis induced by these drugs and even fewer cases of fibrosis. Given the growing use of these drugs, there are implications for monitoring patients on long-term therapy for liver damage. [source] Pharmacy data in epidemiological studies: an easy to obtain and reliable toolPHARMACOEPIDEMIOLOGY AND DRUG SAFETY, Issue 5 2002Taco B. M. Monster MPharmSc Abstract Purpose The agreement between drug use measured in computerized pharmacy records and patient interviews or questionnaires is generally good. However, most investigations on this subject studied selected populations or subsets. We studied the coverage of Dutch pharmacy data for our study cohort, and the agreement between the different sources. Methods We used the data from 8592 subjects of an on-going population-based study, focused on the impact of microalbuminuria (PREVEND). Data on drug use was collected in a questionnaire and at community pharmacies. Drug use was measured in the year preceding the questionnaire. Agreement between the sources was measured using kappa-values, sensitivity and positive predictive value. Results Pharmacy data could be collected for 7568 (88%) of the study cohort. Pharmacy data and questionnaires showed good agreement for antihypertensives, lipid lowering drugs, oral antidiabetics and oral contraceptives, but poor agreement for nitrates, hormone replacement therapy and painkillers. Conclusions Pharmacy data could be collected for a large proportion of our cohort. For chronically used drugs pharmacy data generally agrees well with questionnaires. However, for drugs used for shorter periods, as needed, or also available over-the-counter, the agreement is not so good. Pharmacy data can be a valuable source of drug information in epidemiological studies. Copyright © 2002 John Wiley & Sons, Ltd. [source] Low-Density Lipoprotein Apheresis: Clinical Results with Different MethodsARTIFICIAL ORGANS, Issue 2 2002Rolf Bambauer Abstract: In 40 patients (22 women, 18 men) suffering from familial hypercholesterolemia resistant to diet and lipid lowering drugs, low-density lipoprotein (LDL) apheresis was performed over 84.9 ± 43.2 months. Four different systems (Liposorber, 28 of 40, Kaneka, Osaka, Japan; Therasorb, 6 of 40, Baxter, Munich, Germany; Lipopak, 2 of 40, Pocard, Moscow, Russia; and Dali, 4 of 40, Fresenius, St. Wendel, Germany) were used. With all methods, average reductions of 50.6% for total cholesterol, 52.2% for LDL, 64.3% for lipoprotein (a) (Lp[a]), and 43.1% for triglycerides, and an average increase of 10.3% for high-density lipoprotein (HDL) were reached. Severe side effects such as shock or allergic reactions were very rare (0.5%) in all methods. In the course of treatment, an improvement in general well being and increased performance were experienced by 39 of 40 patients. Assessing the different apheresis systems used, at the end of the trial, there were no significant differences with respect to the clinical outcome experienced with the patients' total cholesterol, LDL, HDL, and triglyceride concentrations. However, to reduce high Lp(a) levels, the immunoadsorption method with special Lp(a) columns (Lipopak) seems to be most effective: ,59% versus ,25% (Kaneka) , (Baxter), and ,29% (Dali). The present data demonstrate that treatment with LDL apheresis of patients suffering from familial hypercholesterolemia resistant to maximum conservative therapy is very effective and safe even in long-term application. [source] | ||||||||||